This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.
Jazz Pharmaceuticals to Report 2018 Third Quarter Financial Results on November 6, 2018
Hamilton, Bermuda – 1 November 2018 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced that it will report its 2018 third quarter financial results on Tuesday, November 6, 2018. The full filing stated:
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) todayannounced that it will report its 2018 third quarter financial results on Tuesday, November 6, 2018,after the close of the financial markets. Company management will host a live audio webcastimmediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss 2018 thirdquarter financial results and provide a business and financial update.
Interested parties may access the live audio webcast via the Investors section of the JazzPharmaceuticals website at http://www.jazzpharmaceuticals.com. Please connect to the websiteprior to the start of the conference call to ensure adequate time for any software downloads thatmay be necessary to listen to the webcast. A replay of the webcast will be archived on the websitefor at least one week.
Audio webcast/conference call:
U.S. Dial-In Number: +1 855 353 7924International Dial-In Number: +1 503 343 6056Passcode: 8048589
A replay of the conference call will be available through November 13, 2018 and accessiblethrough one of the following telephone numbers, using the passcode below:
Replay U.S. Dial-In Number: +1 855 859 2056
Replay International Dial-In Number: +1 404 537 3406
Passcode: 8048589
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focusedon improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and productcandidates with a focus in the areas of sleep and hematology/oncology. In these areas, JazzPharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginaseErwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine)liposome for injection in the U.S. and markets Erwinase®, Defitelio® (defibrotide) and Vyxeos® 44mg/100 mg powder for concentrate for solution for infusion in countries outside the U.S. Forcountry-specific product information, please visit http://www.jazzpharmaceuticals.com/products.
For more information, please visit http://www.jazzpharmaceuticals.com/ and follow us on Twitter at@JazzPharma.
Jazz Pharmaceuticals Contacts:
Investors:
Kathee Littrell
Vice President, Investor RelationsIreland, +353 1 634 7887
U.S., +1 650 496 2717
Media:
Jacqueline Kirby
Vice President, Corporate Affairs & Government RelationsIreland, +353 1 697 2141
U.S., +1 215 867 4910
# # #
For more information on the Bermuda Stock Exchange (BSX), contact the BSX at 1-441-292-7212 or info@bsx.com . Information is also available at bsx.com and on Bloomberg at BSX <GO>.
Established in 1971 the Bermuda Stock Exchange (BSX) is now the leading fully electronic offshore securities market. The BSX specializes in listing and trading of capital market instruments such as equities, debt issues, funds, hedge funds, derivative warrants and Insurance Linked Securities.
The BSX, recognised by the US SEC as a Designated Offshore Securities Market, is a member of the World Federation of Exchanges and is located in an O.E.C.D. member nation. The BSX has Approved Stock Exchange status under Australia’s Foreign Investment Fund (FIF) taxation rules; Designated Investment Exchange status by the UK’s Financial Services Authority; Recognised Stock Exchange by the UK HM Revenue and Customs; Designated Exchange status under Canada’s Income Tax Act and is a member of America’s Central Securities Depository Association.